Europe — EMA
Nutriflex Omega Special Ohne Elektrolyte Novo
GNH USA supplies Nutriflex Omega Special Ohne Elektrolyte Novo (Valine), a nutrition supplement for post‑operative recovery, chronic malnutrition
Request sourcing
What is Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin?
Valine, the active ingredient in Nutriflex Omega Special Ohne Elektrolyte Novo, is a nutrition supplement presented as a nutritional formulation for oral use. It supports metabolic functions and protein synthesis in patients requiring specialized nutritional support.
GNH USA supplies Nutriflex Omega Special Ohne Elektrolyte Novo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.
What is Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin used for?
Nutriflex Omega Special Ohne Elektrolyte Novo is used as a specialized nutritional supplement for patients with increased metabolic demands or impaired nutrient absorption. It is indicated for: - Post‑operative recovery: helps maintain protein balance and energy levels during healing. - Chronic malnutrition: supports weight maintenance and lean body mass in long‑term undernutrition. - Gastrointestinal disorders: provides essential amino acids when oral intake is limited or malabsorptive. - Critical illness: contributes to nitrogen balance and immune support in intensive care settings.
What are the side effects of Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin?
Nutriflex Omega Special Ohne Elektrolyte Novo may be associated with a range of adverse reactions.
Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Abdominal bloating: sensation of fullness or distension. - Diarrhoea: loose stools occurring after initiation. - Metallic taste: transient alteration in oral sensation. - Headache: mild tension‑type headache. - Mild hyperglycaemia: slight rise in blood glucose in susceptible individuals.
Serious or Rare Side Effects: - Anaphylactic reaction: acute, potentially life‑threatening hypersensitivity. - Severe hyperkalaemia: marked elevation of serum potassium. - Hepatic dysfunction: abnormal liver enzyme elevations. - Metabolic acidosis: significant acid‑base disturbance. - Thromboembolic events: rare clot formation. - Renal impairment worsening: decline in kidney function.
What precautions apply to Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin?
When prescribing Nutriflex Omega Special Ohne Elektrolyte Novo, clinicians should consider several safety aspects. - Assess renal function: evaluate baseline creatinine and eGFR before initiation. - Monitor electrolytes: regular checks of sodium, potassium and calcium levels are advised. - Observe blood glucose: patients with diabetes should have glucose monitored. - Watch for allergic history: inquire about previous reactions to amino‑acid formulations. - Adjust for hepatic impairment: consider dose modification in liver disease. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.
What does Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin interact with?
Nutriflex Omega Special Ohne Elektrolyte Novo can interact with other medicines that affect amino‑acid metabolism or electrolyte balance.
Major Interactions (Avoid): - Concurrent high‑dose potassium supplements: may precipitate hyperkalaemia. - Intravenous lipid emulsions containing high amino‑acid loads: increase risk of metabolic overload.
Moderate Interactions (Monitor Closely): - Antidiabetic agents: may require glucose monitoring due to potential hyperglycaemic effect. - Loop diuretics: can alter electrolyte status, necessitating regular electrolyte panels. - Corticosteroids: may amplify protein catabolism, affecting the supplement's efficacy. - Renal replacement therapies: can remove amino acids, reducing therapeutic benefit. - MAO‑MAE